Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology
- Aug 17, 2020
- 1 min read
With a potential IL-12 game-changer
This morning Bristol Myers R&D maestro Rupert Vessey is taking the wraps off one of the biggest cash deals he’s done, focusing on IL-12, and he’s done it with some players he’s been collaborating with for years. Vessey is handing over $475 million in near-term cash for control of Dragonfly’s extended half-life cytokine DF6002 — a monovalent IL-12 immunoglobulin Fc fusion protein designed to fire up a targeted immune response.
Remarkable insights into how major pharmaceutical companies are approaching the future of immuno-oncology. The discussion around innovation, risk, and long-term research investment was fascinating. I appreciate how big storage unit also values organized solutions that support growing needs. Great article highlighting the importance of bold decisions in advancing medical breakthroughs. Great Article.
10.0 0.1 is a helpful resource for router and network settings. This article shares valuable classic car upholstery tips, making seat restoration and interior maintenance easier for enthusiasts. Excellent guide!
Infinite Craft Game transforms basic ingredients into an exciting world of discovery, allowing players to experiment with different combinations and uncover surprising results.